The Technical Analyst
Bone Biologics [BBLG]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Bone Biologics Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-4.68% $1.525
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1.341 mill |
| EPS: | -34.01 |
| P/E: | -0.0400 |
| Earnings Date: | May 05, 2024 |
| SharesOutstanding: | 0.879 mill |
| Avg Daily Volume: | 0.0821 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0400 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0400 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.231 - 1.829 ( +/- 19.54%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-17 | Walsh Deina H | Buy | 12 500 | Employee Stock Option |
| 2024-01-17 | Frelick Jeff | Buy | 25 000 | Employee Stock Option |
| 2024-01-08 | Gagnon Robert E. | Buy | 8 | Non-Employee Stock Option |
| 2024-01-08 | Gagnon Robert E. | Buy | 9 | Non-Employee Stock Option |
| 2024-01-08 | Gagnon Robert E. | Sell | 0 | Common Stock |
| INSIDER POWER |
|---|
| 32.86 |
| Last 92 transactions |
| Buy: 61 072 197 | Sell: 15 856 455 |
Forecast:
16:00 - $1.525
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.525
Forecast 2: 16:00 - $1.525
Forecast 3: 16:00 - $1.525
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.525 (-4.68% ) |
| Volume | 0.0604 mill |
| Avg. Vol. | 0.0821 mill |
| % of Avg. Vol | 73.56 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BBLG
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 9 - 15:44 | buy | $4.66 | N/A | Active |
|---|
BBLG
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-03-06 16:15:00 - Press Release
Bone Biologics Announces Closing Of $2.0 Million Public Offering
Burlington, mass.--(business wire)--bone biologics corporation (“bone biologics” or the “company”) (nasdaq: bblg, bblgw), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share (or common stock equivalent in l.
2024-03-04 09:15:00 - Press Release
Bone Biologics Announces Pricing Of $2.0 Million Public Offering
Burlington, mass.--(business wire)--bone biologics corporation (“bone biologics” or the “company”) (nasdaq: bblg, bblgw), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share (or common stock equivalent in lieu thereof) and acco.
2024-03-01 08:00:00 - Press Release
Bone Biologics Reports Progress With Nb1 Clinical Program
Burlington, mass.--(business wire)--bone biologics corporation (nasdaq: bblg), a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate nb1 into human clinical testing for spinal fusion. following human research ethics committee (hrec) approval last year in australia for the multicenter, prospective, randomized pilot clinical trial, the company reports that three hospital sites have been engaged to participate in the pilot clinical tr.
2024-01-11 08:00:00 - Press Release
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon To Board Of Directors
Burlington, mass.--(business wire)--bone biologics corporation (“bone biologics” or the “company”) (nasdaq: bblg, bblgw), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately robert e. gagnon has been named to the company's board of directors. mr. gagnon fills the seat left by erick lucera, who has resigned effective upon mr. gagnon's appointment. the number of directors of bone biologics remains at four. mr. gagnon is currently chief financ.
2024-01-10 08:00:00 - Press Release
Bone Biologics Regains Compliance With Nasdaq Continued Listing Requirements
Burlington, mass.--(business wire)--bone biologics corporation (“bone biologics” or the “company”) (nasdaq: bblg, bblgw), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from the nasdaq stock market llc (nasdaq) informing the company that it has regained compliance with the minimum bid price requirement under nasdaq listing rule 5550(a)(2) for continued listing on the nasdaq capital market. bone biologics is now in compliance with all.
Latest News
2023-11-17 08:37:36 - InvestorPlace
Why Is Bone Biologics (BBLG) Stock Down 38% Today?
Bone Biologics (NASDAQ: BBLG ) stock is falling on Friday after the medical device company's shares underwent a major rally the day prior. That rally was caused by heavy trading of BBLG stock.
2023-11-16 07:46:41 - InvestorPlace
Why Is Bone Biologics (BBLG) Stock Up 84% Today?
Bone Biologics (NASDAQ: BBLG ) stock is rocketing higher despite a lack of news from the medical device company on Thursday. There are no new press releases or filings with the Securities and Exchange Commission that explain why BBLG stock is up today.
2023-07-11 15:06:16 - PennyStocks
Penny Stocks to Watch: Why Is ELOX Stock Skyrocketing?
Most traders dream of hitting it big, and penny stocks are some of the most attractive for day traders. It can be any given session where we see at least a handful of cheap stocks under $5 explode.
2023-06-21 07:49:41 - Benzinga
Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month - Bone Biologics (NASDAQ:BBLG), Fresh2 Group (NASDAQ:FRES)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2023-06-15 09:22:00 - Market Watch
Bone Biologics stock plummets more than 50% after stock offering prices at deep discount
Shares of Bone Biologics Corp. BBLG plummeted 51.9% toward a record low in premarket trading Thursday, after the developer of regenerative medicine for bones announced the pricing of its relatively large stock offering at a deep discount. The company raised $5 million, as it said overnight that it sold 2.54 million shares, which represented 15.2% of the shares outstanding, at price of $1.97 per share.
2023-06-15 08:40:13 - InvestorPlace
Why Is Bone Biologics (BBLG) Stock Down 52% Today?
Bone Biologics (NASDAQ: BBLG ) stock is breaking down on Thursday after the company announced the details of a public share offering. Bone Biologics has revealed its public offering prices shares of BBLG stock at $1.97 each.
2022-12-14 11:51:20 - PennyStocks
Penny Stocks To Buy Now? 10 Stocks Under $1 To Watch
2022-12-12 14:51:07 - PennyStocks
7 Hot Penny Stocks Under $1 To Watch This Week
Penny stocks to watch trading under $1 right now. The post 7 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-03-17 13:54:13 - PennyStocks
Best Penny Stocks To Buy? 4 Biotech Stocks To Watch Right Now
2022-01-10 15:50:48 - InvestorPlace
BBLG Stock Alert: 7 Things to Know as Bone Biologics Skyrockets Today
Today, investors in Bone Biologics and BBLG stock are seeing some serious gains as investors dive into niche small caps. The post BBLG Stock Alert: 7 Things to Know as Bone Biologics Skyrockets Today appeared first on InvestorPlace.